FIELD: selection and preparation of antibodies.
SUBSTANCE: method of determining the suitability of an antibody solution for inclusion in a pharmaceutical composition involves establishing an upper viscosity limit; calculation proceeding from information on primary structure of structural information on antibody in solution, total charge and charge asymmetry. Primary structure includes: the amino acid sequence of the variable light chain domain (VL) and the amino acid sequence of the variable heavy chain (VH) domain; obtaining: a first scaling factor, which corresponds to common charge, of second scaling factor, which corresponds to charge asymmetry; calculation of the index based on the target function, containing scaling factors, total charge and charge asymmetry, wherein the index is the viscosity of the antibody solution; and determining that the antibody solution is suitable for inclusion in the pharmaceutical composition, taking into account the above value not exceeding the upper viscosity limit. Also disclosed is a version of a method for determining the suitability of a target antibody solution for inclusion in a pharmaceutical composition, method of selecting between a first antibody solution and a second antibody solution for inclusion in a pharmaceutical composition.
EFFECT: group of inventions provides higher probability of technical success for effective promotion of new therapeutic agents based on mAb in clinical practice.
28 cl, 19 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR IMPROVING ANTIBODY STABILITY | 2014 |
|
RU2711719C2 |
METHODS AND COMPOSITIONS INCLUDING PURIFIED RECOMBINANT POLYPEPTIDES | 2014 |
|
RU2793783C1 |
VERSIONS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY | 2018 |
|
RU2813990C2 |
LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
ANTIBODY THAT BINDS TO VEGF AND IL-1BETA, AND METHODS OF USE THEREOF | 2019 |
|
RU2816476C2 |
IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
ANTIBODIES TARGETING GALACTAN-BASED O-ANTIGEN FROM K.PNEUMONIAE | 2015 |
|
RU2759950C2 |
DOUBLE SPECIFICITY ANTIBODIES | 2014 |
|
RU2732032C2 |
ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2739946C2 |
ANTIBODY CONTAINING PREPARATION | 2017 |
|
RU2748046C2 |
Authors
Dates
2021-02-02—Published
2014-11-26—Filed